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The factor V Leiden mutation is the most common
genetic risk factor for deep vein thrombosis: it is
present in about 5% of the white population. The
risk of deep vein thrombosis among women who
use oral contraceptives is greatly increased by the
presence of the mutation. The same seems to be
true of the risk of postpartum thrombosis. Several
authors have called for all women to be screened
before prescription of oral contraceptives and
during pregnancy. Such a policy might deny effec-
tive contraception to a substantial number of
women while preventing only a small number of
deaths due to pulmonary emboli. Moreover, in
pregnancy the ensuing use of oral anticoagulation
prophylaxis might carry a penalty of fatal bleeding
that is equal to or exceeds the risk of death due to
postpartum thrombosis. It might pay, however, to
take a personal and family history of deep vein
thrombosis when prescribing oral contraceptives
or at a first antenatal visit to detect women from
families with a tendency to multiple thrombosis.
Our recent reports on an increased risk of venous
thrombosis in women who use oral contraceptives and
are also carriers of a thrombogenic mutation (factor V
Leiden)1 2 prompted discussions about the possible
benefit of screening for this coagulation defect before
oral contraceptives are prescribed.3"8 Also, the spectre of
screening in other risk situations, such äs pregnancy, is
being raised.'' We believe that some perspective on the
epidemiological data is necessary.
Venous thrombosis is a rare event, especially in young
people, and, if limited to the limbs, is benign. By calcu-
lating back from a population based case-control study,
we estimated that the incidence rate of venous
thrombosis of the legs in women aged 15 to 49 years is
2.1 per 10 000 women years.1 Although estimates on
the prevalence of the factor V mutation vary, a fair
approximation is that about 5% of the white population
will be carriers. The mutation leads to a relative resist-
ance of coagulation factor V to breakdown by activated
protein C (APC resistance). This reduces the efficiency
of the blood's own anticoagulation System and therefore
increases the propensity to venous thrombosis.10
Oral contraception
In our earlier study1 we estimated that the incidence
of deep vein thrombosis of the legs among women who
did not use oral contraceptives and were not carriers of
the mutation was 0.8 per 10 000 women years; this
increased to 3.0 per 10000 women years among
women who used oral contraceptives and to 5.7 per
10 000 women years among carriers of the factor V
mutation. Among women who had both risk factors
(carriers of the factor V mutation who used oral contra-
ceptives) the incidence became 28.5 per 10 000 women
years. These differences point to a synergistic effect äs
the additional risk for both risk factors together is
greater than the sum of each of the separate increases in
risk; in fact the relative risks are almost multiplicative.1
The calculation of incidences from our case-control
study was approximate, however, and the relevant rela-
tive risks had wide confidence intervals. In a
pharmacoepidemiological Imkage study in Britain, äs
well äs in a back calculation from the Oxford data of the
World Health Organisation's case-control study on
venous thrombosis, the incidence of venous thrombosis
among non-users of oral contraceptives—about 0.4 per
10 000 woman years1' l:—was lower than we had calcu-
lated, which might be due to the investigation of slighdy
younger age groups (15 to 40 or 44 years) or to differ-
ences in case definition and ascertainment.
The worst outcome for a young woman with deep
vein thrombosis is that she develops fatal pulmonary
emboli. The case fatality of venous thrombosis among
people aged less than 40 years in hospitals in the United
States is estimated at 2%." This estimate is an overall
figure and includes people with severe trauma or who
have had major surgery, possibly with repetitive and
massive pulmonary embolism. It might be too high
when applied to young women who develop thrombosis
during the use of combined oral contraceptives—a case
fatality of l % might be closer to reality. However, if the
"worst case" 2% is multiplied by our estimate of the
incidence, the use over one year of oestrogen and
progestogen contraception in women who are carriers
of the mutation would lead to a death rate from pulmo-
nary emboli of 5.7 per 100 000 a year.
PREVALENCE AND RISK
This risk applies to only a small segment of the popu-
lation of young women. In the Netherlands in our
population based case-control study about 3% of the
control group were carriers of the mutation.14 In a study
in the United States of a large group of middle aged,
male physicians the prevalence of the mutation was
about 6%.15 The highest population prevalence, 15%,
has been found in Greece6 and southern Sweden.8 In
contrast, the prevalence of the mutation in Asian and
African countries seems much lower.6 In the Nether-
lands in 1994, 45% of women aged 15-49 years
currently used oral contraceptives; peak use was 80% at
age 20 to 24, but it was already 53% at age 15-19 and
still about 20% over the age of 40.16 In Britain the use of
oral contraceptives is generally held to be lower—about
50% at the younger ages, and much lower at older ages.
The annual risk of death remains small, even among
camers of the mutation who use oral contraceptives. On
the other hand, every year in each industrialised country
a few young women die of pulmonary emboli. Some of
these profound individual tragedies will be due to the
combination of the pill and the mutation.
SHOULD WE SCREEN?
What advice should we give to ensure the greatest
public good? If we want to be extremely risk avoiding we
might screen all young women who are on the pill or
who intend to Start using it. Such a policy might deny
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oral contraceptives to at least 3% to 6% of women, with
the ensuing risk of other problems: related strain due to
unappealing methods of contraception and contracep-
tive failures resulting in unwanted pregnancies and their
consequences." Therefore, unless our estimates prove
too conservative or unless other risks—such äs arterial
thrombosis (myocardial infarction or stroke)—are also
determined by the same combination of risk factors, we
do not support universal screening before prescription.
Moreover, the screening task would be formidable.
From a death rate from pulmonary embolus of 5.7 per
100 000 a year, it follows that about 20 000 women
positive for factor V should be denied the use of oral
contraceptives during one year to prevent one death. At
an estimated population prevalence of the mutation of
l in 20, 400 000 young women would need to be
screened to find them. Of course only 40 000 women
need to be screened if it is assumed that the benefit
accrues over 10 years of non-use of oral contraceptives;
that extrapolation is uncertain äs the incidence of
thrombotic events is higher during the first year of use.
If the population prevalence of the mutation is higher,
say l in 10, 200 000 women would still need to be
screened to prevent one death. On the other hand, if we
use lower figures for the incidence of venous thrombo-
sis, for its fatality, and for the prevalence of factor V Lei-
den (for example, a baseline incidence of 0.5 per 10 000
women years, a case-fatality of l %, and a prevalence of
3%) the number of women who need to be screened to
prevent one death might exceed two million.'8
The cost and reliability of the screening test(s) are
also variable: it depends to a large extent on the
accuracy of the coagulation test that detects activated
protein C resistance (which is the coagulation
consequence of the mutation), the number of times that
the coagulation test has to be followed by DNA
determination, or the choice for a direct DNA deter-
mination without coagulation testing. Even at nominal
laboratory costs for testing for activated protein C
resistance and DNA confirmation, screening for factor
V Leiden before prescription of contraceptives is
unlikely to stand the competition for resources
with other medical screening and therapeutic
interventions.
PREVIOUS VENOUS THROMBOSIS
If a woman has already had a venous thrombosis the
reasoning over whether or not to screen might be differ-
ent. No data exist about young women who continue
taking the pill after a fest deep vein thrombosis. A pre-
vious venous thrombosis, however, is known to be a
strong risk factor for a further thrombosis." Evidence
now exists that recurrence rates of idiopathic venous
thrombosis—that is, without a clear precipitating factor
such äs trauma or surgery—are higher in carriers of the
factor V mutation than in non-carriers.20 These data
pertain to middle aged male physicians, however, and
we do not know whether they apply to young women
with a history of thrombosis who use contraceptives.
In the recent past, when the factor V Leiden mutation
was still unknown, most doctors were already advising
young women with a history of venous thrombosis to
consider other modes of contraception, such äs
progestogen-only pills or barrier methods, if diese were
acceptable to her and her partner. The advice seemed
more urgent if the thrombosis had happened soon after
starting oral contraceptives without any other precipi-
tating factors, or if pulmonary emboli had developed.
The wisdom of this advice is borne out by a follow up
study that showed how recurrence rates of idiopathic
thrombosis were lower in women who had stopped
using oral contraceptives than in women who had never
taken the pill.2' (Of course if there is a clear precipitat-
ing factor—say, an arthroscopy of the knee joint—such
Oral contraception, pregnancy, and
factor V Leiden
• Women who carry the factor V Leiden mutation
and use oral contraceptives have a much greater
risk of deep vein thrombosis
• Routine screening for the factor V Leiden muta-
tion before prescription of oral contraceptives
would deny effective contraception to about 5% of
white women, while preventing only a small
number of fatal pulmonary emboli
• If routine screening for the factor V Leiden
mutation during pregnancy is followed by routine
anticoagulation prophylaxis, the number of cases
of fatal bleeding might equal or exceed the number
of fatal pulmonary emboli that are prevented
• Taking a personal and family history of deep vein
thrombosis when prescribing oral contraceptives,
or at a first antenatal visit, will detect people from
families with a tendency to multiple venous throm-
bosis and might be worthwhile
a thrombosis will not count äs heavily äs a purely
idiopathic one during pill use.) Doctors will continue to
give the same advice to a young woman with thrombo-
sis, irrespective of her factor V Status. When the woman
is a carrier of the mutation she will have a raised
baseline risk, which gives firmer ground for advising her
to opt for other modes of contraception. The advice
might become mandatory if the woman is a
homozygous carrier of the mutation: in homozygotes
the risk of venous thrombosis is 50 to 80 times the base-
line risk, and oral contraception might increase this to
more than a hundredfold.22 The same might be true if a
woman carries two different thrombogenic mutations—
for example, factor V Leiden combined with deficiency
of protein C, protein S, or antithrombin.'
FAMHJAL VENOUS THROMBOSIS
Should we take a family history of venous thrombosis
at fest prescription of oral contraceptives? Yes—the
main advantage of the family history is that it may help
to detect families with a "thrombophilic tendency" (that
is, when several members have deep vein thrombosis,
often multiple, at younger ages or without clear precipi-
tating risk factors).23 The factor V mutation is found in
more than half of these families, and homozygotes are
more common (when both parents have the mutation).
Also, other rare genetic thrombophilia disorders can be
detected by taking a family history: deficiency of protein
C, protein S, or antithrombin. Although their rarity has
precluded the exact calculation of their effect when
combined with the use of oral contraceptives, the over-
all picture is one of a rather similar potentiation of risk.
Moreover, in families with a tendency to multiple
thrombosis there is more often a combination of the
factor V mutation and one of the rarer mutations. Pre-
sumably, these families carry still other, presently
unknown, genetic or other risk factors for venous
thrombosis.2' The detection of such families is worth
while from a clinical point of view: even if no known
mutations are found but there still is a clear family his-
tory of venous thrombosis, clinical wisdom might
dictate caution in prescribing combined oestrogen and
progestogen contraceptives. The main disadvantage of
the family history is that it is not very sensitive—for
example, when a person has few relatives the possibility
of a family history rieh in venous thrombosis is
obviously much reduced. Nevertheless, if the family
history is positive, the prescribing doctor has Infor-
mation that should certainly be taken into account.
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Prepnancy
The postpartum pcriod is when womcn are often at
greatest nsk of pulmonary emboh. Should all pregnant
women bc screened for the mutation? The overall
matcrnal death rate due to pulmonary embolism has
been esnmated for the Netherlands over a long period
(1952-79) äs 5 per 100 000 deliveries.25 Lower
estimates vvere obtained in the early 1980s for Britain
(0.3 per 100000 deliveries (0.5 per 100000 after
caesarean section)) and the United States (1.2 per
100000).·°" If half of these events were to happen
among, say, the 5% women who carry the factor V
mutation/ the risk of puerperial death due to
pulmonary embolism might be äs high äs l in 2000 or
äs low äs l in 15 000 among women with the mutation.
In principle these events might be prevented by prophy-
lactic anticoagulation.
Oral anticoagulation, however, carries its own risk.
Under conditions of optimal monitoring, two to three
patients per 100 treatment years will develop severe
bleeding (necessitating admission to hospital). The risk
of fatal bleeding or intracranial bleeding that leads to
lifelong handicap is about 0.5 patients per 100
treatment years.28 29 This figure applies to the overall
population that receives long term oral anticoagulation,
which is elderly and often has major underiying disease
(malignancies) or which is in need of high intensity
anticoagulation—for example, for artificial cardiac
valves. In general the risk of severe bleeding during
chronic treatment depends on the achieved level of
anticoagulation and is lower among younger people, but
it is higher among women.28 In the experience of the
Leiden thrombosis centre, which has published similar
overall complication rates, the risk among younger
women who receive short term anticoagulation for
prophylaxis or treatment of venous thrombosis is not
materially different from the overall risk (F J M van der
Meer, personal communication). Perhaps this is
because these courses of treatment are short, so they
bear the brunt of the first weeks of treatment, when the
right dosage is still being sought and bleeding complica-
tions are more frequent. As a course of prophylactic
treatment takes about six weeks (about one tenth of a
treatment year), a deadly or debilitating complication of
postpartum anticoagulation prophylaxis might affect l
in 2000 young mothers. This penalty of anticoagulation
prophylaxis equals the highest estimate of risk of death
due to puerperial thrombosis among women positive for
factor V Leiden.
Such comparisons between benefits and risks are
extremely tenuous, of course, and mainly illustrate our
lack of knowledge. The published estimates of risk of
death due to puerperial thrombosis vary widely, and the
fraction wherein factor V Leiden might have a role is
known only approximately. The estimate of the risk of
prophylactic oral anticoagulation in young women is
based on small numbers and subject to chance
Variation, äs the indication is relatively rare.
Nevertheless, the provisional balance seems to indicate
that the benefit of treatment equals its penalty, which
does not immediately point to the necessity of an over-
all screening and anticoagulation prophylaxis during
and after pregnancy.
IIMITATIONS
The risk-benefit calculations may alter completely for
prophylactic interventions that carry no penalty, even if
they are less effective. For example, tight elastic
stockings are a nuisance but only slightly less effective
than pharmacological anticoagulation (at least in
preventing deep vein thrombosis after hip surgery), and
they certainly do not cause any bleeding.30 In between
these two extremes (füll oral anticoagulation v elastic
stockings) it remains to be determined whether
Scanning electron micrograph of thrombus of red blood cells
inside blood vessel
intermediary pharmacological regimens, such äs low
dose conventional heparin, low dose low molecular
weight heparin, or "low intensity" warfarin (aiming at
an international normalised ratio below 2.0), have a
place. Data are scarce, however, about the relative effec-
tiveness or complication rates of these agents when used
for several weeks or months.
An important clinical factor that we could not take
into account in this calculation is a possible difference
in the risk of puerperial thrombosis between women
with and without a history of thrombosis. Although the
studies are relatively small, evidence exists of a roughly
10% recurrence rate of deep vein thrombosis during or
after pregnancy.21 31 If we accept a similar mortality of
2% this will tut the balance in favour of anticoagulation
prophylaxis among women with a history of thrombosis,
regardless of whether they are factor V positive. Again
the concern about homozygotes or women with
combined defects might be stronger. For the same rea-
sons äs with use of oral contraceptive, taking the
personal äs well äs the family history of venous throm-
bosis of a woman at first prenatal consultation might be
worth while: it might detect individuals and families
with thrombophilia where clinical judgment might be
different.32
The family
Most advice given to carriers of factor V Leiden
mutation derives from what is generally advised to
members of families with inherited thrombophilia due
to deficiency of protein C, protein S, or
antithrombin.33 34 Such families first come to the atten-
tion of coagulation specialists because one proband
mentions that he or she is now the second, third, or
fourth member of the family developing venous throm-
bosis without any clear precipitating factor. Often the
thromboses developed at young ages or were multiple.
Families with a tendency to multiple thrombosis are
likely to harbour more than one genetic or environmen-
tal risk factor (or have simply had "bad luck").' '" 2t
These high risk families are rare and often receive highly
personalised care in specialised centres. The Situation
has been completely altered, however, because of the
high frequency of factor V mutation among patients
with deep vein thrombosis (up to 20%). Screening for
the mutation seems likely to be adopted in the routine
investigation of many patients with venous thrombosis.
This will yield increasing numbers of thrombotic
patients with the mutation, many without a clear family
history of thrombosis.
What should we teil family members, half of whom
might also carry the mutation? To date we have no data
on family members of consecutive patients who are not
members of families with a tendency to multiple throm-
bosis. A woman with venous thrombosis and factor V
Leiden mutation might have daughters or sisters who
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take the contraceptive pill These relatives have at least
one family member with venous thrombosis who carnes
üie mutanon Should we offer them screemng' Perhaps
they should first be told about the benefits and nsks of
knowmg and asked about the acceptabihty of other
forms of contraception The advice to be screened
might be firmer if other first degree family members are
found to have had deep vem thrombosis at young ages
or without clear nsk factors (which would suddenly
make the family mto one with a tendency to multiple
thrombosis), or if the mdex patient is a homozygote or
carnes combmed thrombogenic defects The clmical
Situation of the patient and the other family members
will contmue to direct the doctor's advice, radier than
the mere presence or absence of a mutation
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Brucellosis is now rare in Bntam, and most cases are
imported or contracted m a laboratory settmg We
present the case of a vetennary scientist who contracted
the condition while working on the products of con-
ception from animals
Case history
A 24 year old man who was studying immunology at a
postgraduate medical school jpresented to this hospital's
casualty department in July 1995 with a 17 day history of
high fevers, mght sweats, dry cough, and myalgia He also
complamed of pain and discharge from a lower left molar
tooth He had no medical history and was takmg no regu-
lär drug treatment. A travel and occupanonal history
showed that he had hved in Himachal Pradesh in northern
India until March 1995, when he moved to London. He
had previously quahfied äs a vetennary surgeon, before
studying for a microbiology degree between 1993 and
1995. Dunng this nme he had performed regulär
experiments on the products of concepüon from cattle and
sheep to mvesügate possible infecüous causes of aboroon.
On exammation at admission the panent had a fever
of 38 5°C, a sohtary cervical lymph node measunng
l cm χ 0 5 cm in size, a resting tachycardia of 110 beats
per mmute, and a palpable splemc np. Exanunaüon of
his mouth showed pus discharging from the lower left
third molar tooth.
Iniaal mvestigations showed raised mflammatory
markers (erythrocyte Sedimentation rate 34 mm in the
first hour and C reacnve protem concentrauon of 84
U/l) and white cell count of 4 8 χ IO'/Ι Three blood
films for malana parasites were neganve Standard hver
function tests yielded abnormal results (with a raised
serum alkahne phosphatase concentration of 405 U/l, a
raised γ-glutamyltransferase concentration of 410 U/l,
and a raised serum aspartate ammotransferase concen-
tration of 248 U/l); the serum bihrubm concentration
was at the upper end of the normal ränge, at 17 μτηοΐ/ΐ.
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